omico home graphic
omico home graphic

Together, cancer meets its match

Omico is changing the way we fight cancer by accelerating access to precision oncology. We are a national, independent, not-for-profit organisation, uniting Australia’s world-class cancer institutes, researchers, clinicians, industry partners and government like never before. By leveraging a nationwide network of expertise and resources, we aim to improve outcomes for all Australian cancer patients. With fast-tracked molecular and genomic screening, biomarker-led trial set up and patient enrolment from the entire nation, we’re accelerating access to next generation treatments and preventive strategies.

What we do

video_icon

We aim to improve outcomes for Australians living with cancers, by:

  • Increasing access to genomic profiling to detect unique genetic variations in cancer patients’ tumours to identify potential matches to new targeted treatments options
  • Growing and streamlining biomarker-led clinical trials by expediting patient recruitment and site setup, and attracting more international trials to Australia, facilitating faster transitions from discovery to clinical application
  • Advancing a research-led model of care as to open new treatment pathways for patients, and supporting drug development and cancer research through the collection of real-world data

How our molecular screening works

If you or someone you know has advanced or incurable cancer or is at high-risk for cancer (due to hereditary conditions) then:

  • Your doctor completes an online referral form
  • You sign a consent form
  • Omico assesses the genes and other molecules in your cancer tissue
  • Our experts match results to an existing therapy or clinical trial of a new drug
  • Process takes 8 to 10 weeks

Our progress

10,500+ Patients screened
800 Referring clinicians
6,454     Patients with a treatment recommendation
786 Clinical trial referrals (C1/C2)

How Omico can help you

industry icon

Industry

Meet your clinical trial objectives sooner and for a lower cost.

researchers icon

Researchers

Meet intellectually-stimulating research that changes cancer care and transforms lives.

clinicians icon

Clinicians

Meet accelerated access to innovative new therapies for your patients.

patients icon

Patients & Families

Meet new ways of treating your cancer.

government icon

Government

Meet an opportunity to advance the nation’s health and wealth.

advocacy icon

Advocacy Groups

Meet a partner that can help you make a real difference for those affected by cancer.

Who we work with

client-logo
client-logo
client-logo
client-logo
client-logo
client-logo
client-logo
client-logo
client-logo
client-logo
client-logo
client-logo
client-logo
client-logo
client-logo
client-logo
client-logo
client-logo
client-logo
client-logo
client-logo
client-logo
client-logo
client-logo
client-logo
client-logo
client-logo
client-logo
client-logo
client-logo
client-logo
client-logo
client-logo
client-logo
client-logo
client-logo
client-logo
client-logo
client-logo
client-logo
client-logo
client-logo
client-logo
client-logo
client-logo
client-logo
client-logo
client-logo
client-logo
client-logo
client-logo
client-logo
client-logo
client-logo
client-logo
client-logo
client-logo
client-logo
client-logo
client-logo
client-logo
client-logo
client-logo
client-logo
client-logo
client-logo
client-logo
client-logo
client-logo
client-logo
client-logo
client-logo
client-logo
client-logo
client-logo
client-logo
client-logo
client-logo
client-logo
client-logo
client-logo
client-logo
client-logo
client-logo

Recent news

Prof. David Thomas will Address the National Press Club of Australia

Hear from the 'Godfather' of rare cancer science and precision oncology, Professor David Thomas, announcing the latest groundbreaking cancer research outcomes in the country on Wednesday 26th June, coinciding with Rare Cancers Awareness Day and the National Health Journalism Awards.

Read more

Omico achieves major milestone!

5000 Australians with toughest cancers referred to PrOSPeCT for free comprehensive genomic profiling. The nation’s largest cancer genomics initiative PrOSPeCT (Precision Oncology Screening Platform Enabling Clinical Trials) has reached a major milestone this month with over 5,000 Australians, diagnosed with hard-to-treat cancers with very limited treatment options, receiving referrals for free comprehensive genomic profiling (CGP) of their cancer.

Read more

Update March 2024: Omico and PrOSPeCT

PrOSPeCT (Precision Oncology Screening Platform Enabling Clinical Trials) is our landmark precision oncology initiative, enabled by public-private funding and partnerships totalling over $185M, including $61.2M grant funding from the Australian Government.

Read more
More news

Let’s work together to make a difference.

Get in touch